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ABSTRACT OF THESIS 
 
 
THE IMPACT OF BONE MARROW TRANSPLANTION 
 ON PATIENTS WITH PSYCHIATRIC DIAGNOSES:  
MEDICATION ADHERENCE ASSESSMENT 
 
We investigated whether there is a measurable difference in medication utilization 
for psychiatric conditions before and after bone marrow transplantation (BMT). Previous 
studies have identified a potential association between psychiatric conditions and immune 
function. We hypothesized that medication utilization for psychiatric diagnoses would be 
impacted by BMT. This study was a retrospective, quasi-experimental cohort design. Two 
measurements of medication utilization, proportion of days covered (PDC) and medication 
possession ratio (MPR) were calculated for each included Medispan-defined class of 
medications before analyzing changes in PDC and MPR at the patient level. There was a 
statistically significant decrease in the number of raw prescriptions as well as in PDC value 
in the 2 years after BMT as compared to before the procedure. We found a decrease in 
medication utilization after BMT across the measured medication classes, indicating a 
potential resolution of psychiatric symptoms and a potential impact on the associated 
pathophysiology. These results provide support for the premise that genetic factors 
associated with immune function play a role in psychiatric illness. 
KEYWORDS: bone marrow transplant, psychiatric conditions/diagnoses, psychiatric 
medications, medication adherence 
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Section One: Introduction 
Overview 
 Current healthcare practices require disease states to be assessed through 
objective assessments and clearly documented outcomes associated with the present 
condition.1 Psychiatric conditions, however, are not assessed in this manner. Despite 
4.5% of Americans suffering from a serious mental illness (equaling 11.2 million 
people), patients diagnosed with mental health conditions have a higher difficulty being 
able to receive treatment.2 The underlying cause of delays in receiving treatment include 
lack of objective diagnostic tests, a paucity of clinical trial data due to the amount of time 
required for medication trials, and the patients’ overall wellbeing adversely affecting their 
ability to consistently follow treatment plans. Consequently, patients contend with 
increased hospitalizations, higher likelihood of polypharmacy and a lower quality of life.  
 Difficulties in identifying diagnostic tools have led researchers to explore 
different genetic components that may be either associated with psychiatric illnesses or 
potential treatment options for these patients. Over the past decade, researchers have 
utilized genetically altered mouse models in order to uncover the role of previously 
understudied genes and genetic markers. Of particular note, mice that lack 
the Hoxb8 gene, which was thought to be associated only with the production of 
microglia during gestation, display psychiatric tendencies primarily associated with 
obsessive-compulsive disorder (OCD).3 Interestingly, this behavior is reversed by bone 
marrow transplantation (BMT), suggesting that there is an immune component to 
psychiatric pathophysiology.4 Genome-wide associated studies (GWAS) have found 
additional associations between genes expressed by the immune system and 
schizophrenia. Upon further investigation, case reports have shown a similar relationship 
for patients receiving allogeneic bone marrow transplantation and reduction of 
psychiatric symptoms. The work presented in this thesis investigates the relationship 
between the immune system and psychiatric illness through the evaluation of medication 
use before and after allogeneic BMT.  
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Psychiatric Conditions and Difficulty in Effectively Diagnosing and Treating 
 Unlike other disease states, psychiatric conditions do not have objective 
laboratory measurements and standardized diagnostic tests to pinpoint a diagnosis. 
Consequently, the average time between first symptoms and diagnosis is approximately 
11 years.5 This delay is primarily due to the subjective nature of diagnosing psychiatric 
conditions — clinicians must rely primarily on interpreting symptoms instead of proof of 
a primary cause. Scoring systems are utilized in diagnosing psychiatric conditions and 
consist of a review of patients’ self-reported symptoms that may or may not meet criteria 
for a specific diagnosis. These scales are diverse, generally being condition-specific in 
use and following different classifications depending on what governing board has 
established and applied the specific scoring system’s use.6 Common scales include 
Comprehensive Psychopathological Rating Scale (CPRS), Global assessment of 
functioning (GAF), Major Depression Index (MDI), Positive and Negative Syndrome 
Scale (PANSS), and Generalized Anxiety Disorder 7 (GAD-7).6 Without an appropriate 
diagnosis, patients suffer from decreased quality of life and increased symptoms that lead 
to more frequent hospitalizations and/or worse  outcomes. 
 Primary diagnostic tools utilized for mental health patients generally follow the 
international guidelines called the Diagnostic and Statistical Manual of Mental Disorders 
(DSM), currently in its 5th edition.7 These guidelines outline specific psychiatric 
conditions and diagnostic criteria based on the scale of common symptoms associated 
with the corresponding diagnosis. This set of guidelines provides a more in-depth 
analysis of symptoms for each disease state and is the primary assessment of most 
psychiatric conditions. The DSM-V has been assembled by mental health specialists and 
also provides updates according to what may change in current practice. The DSM is 
regarded as reliable with clinicians understanding to use social sciences that may apply to 
their specific patient more than those outlined in the guidelines.8 
 In addition to the difficulty in diagnosing patients with psychiatric conditions, 
extensive time and effort is required to find effective treatment regimens. The average 
period to optimize a patient’s appropriate long-term treatment is three to five years.5 This 
delay is the result of the prolonged amount of time psychiatric medications require to 
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reach steady-state, the myriad of adverse effects associated with these medications, and 
ultimately the patient’s ability to continue therapy on their own.       
 Patients categorized as having a serious mental health disorder have the most 
difficult time with therapy management compared to patients with other mental health 
diagnoses.5 Serious mental health disorders are defined as those that are treatment-
resistant or those that cause debilitating diseases including schizophrenia, obsessive-
compulsive and/or other spectrum disorders.4 In fact, it was found in 2018 that only 
64.1% of patients with serious mental health disorders receive treatment for their illness 
and that treatment-resistant patients account for 85% of mental health associated 
hospitalizations.9  
This patient population struggles with normal day-to-day operations due to debilitating 
symptoms that may lead to delirium, psychosis or extreme fatigue. Because of decreased 
ability to focus on daily tasks, many times these patients struggle with adhering to their 
medications, leading to worsening symptoms that require hospitalization or 
institutionalization.  
 Cost is a primary concern for all aspects of care, with hospitalizations responsible 
for a large component.10 In Table 1.1, the average cost and length of hospitalized stay 
(LOS) for acute disease exacerbations of a variety of diagnoses are depicted.11 This data 
demonstrates that patients with schizophrenia typically are subject to lengthy stays that 
carry significant cost. Although cost during their hospitalizations may not be as high for 
patients with mental health conditions as those with certain cancer or infectious disease 
diagnoses, the average LOS was higher for schizophrenia and other serious mental health 
conditions.10,12   
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Table 1. 1  Hospitalization Average Length of Stay and Cost for Chronic 
Conditions11 
 
 
 
 
Patients with mental health disorders not only struggle with acute exacerbations, 
but additionally many patients are uninsured or covered by Medicare. Table 1.2 shows 
the impact of mental health diagnoses to both Medicare and other systems that provide 
care to the uninsured. This data emphasizes the financial burden created by the ongoing 
care of these patients and what may take place with exacerbated symptoms leading to 
hospitalizations. Finding any objective biomarker for healthcare professionals would 
revolutionize the diagnosis and treatment of patients with psychiatric diagnoses, resulting 
in increased patient treatment success, fewer hospitalizations and decreased costs. While 
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longitudinal counseling, behavioral intervention and pharmacotherapy can provide 
efficacious long-term management, these treatments are not curative. Advancing our 
knowledge of the underlying genetic components of mental health disorders is critical 
and could lead to treatment advances that are transformative to both individual patients 
and to our overburdened healthcare system. 
 
Table 1. 2 Psychiatric Conditions and Average Cost with Associated Hospital 
Length of Stay (LOS)9 
 
     
 
Medication Use in Patients Diagnosed with Psychiatric Illnesses 
 Most psychiatric diagnoses require pharmacologic intervention as a major 
component of therapy. Assessing a patient’s medication utilization is a method for 
healthcare professionals to not only measure the patient’s adherence to their therapy but 
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also evaluate the effectiveness of the medication in treating the condition.13 Appropriate 
medication use, referred to as adherence, has extensive implications for patient care. 
Proper medication adherence can increase a patient’s quality of life while decreasing 
hospitalizations.13 In fact, non-adherence accounts for approximately 50% of treatment 
failures, 25% of hospitalizations and 125,000 deaths annually.14,15 
 Patients with mental health illnesses struggle with medication management and 
adherence to a greater extent than the general population. Table 1.3 depicts the 
medication adherence percentages of common mental health conditions.16 These are 
considerably lower and more variable when compared to adherence rates for common 
conditions including hypertension (50-70%), congestive heart failure (40-60%), diabetes 
mellitus (approximately 35%), and patients taking oral antibiotics for skin infections (57-
78%).17-20 
 
Table 1. 3 Psychiatric Diagnoses and the Associated Adherence Percentages 
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These lower adherence rates compared to other conditions are likely due to the 
difficulties that patients with severe mental health disorders experience, such as their 
inability to complete daily tasks. This statistic also emphasizes the necessity to find a way 
to assist patients with mental health diagnoses in managing their diseases more 
efficiently.  
 Nonadherence affects mental health patients in a variety of ways. One systematic 
review of antipsychotic use in bipolar and schizophrenic patients summarizes results 
from 38 studies consisting of 51,796 patients. The primary objective was to assess which 
factors contributed to non-adherence and the degree to which each was associated. For 
both bipolar and schizophrenic patients, it was found that substance abuse, cognitive 
impairments, a lower level of education, poor therapeutic alliance, high intensity of 
delusional symptoms, and low socioeconomic status were associated with poor 
adherence. To help overcome some of these barriers, this review found that building a 
personal relationship with the patient, providing more patient education and giving 
assistance in overcoming substance abuse led to increases in antipsychotic adherence and 
minimization in symptoms.21  
 In a study of 87 patients suffering from schizophrenia, overall self-reported 
adherence and potential factors that impacted that adherence were examined. Of the 87 
patients, adherence was reported at approximately 50% with primary reasons for lower 
adherence being patients with lower insight and previous treatment-related trauma.  This 
assessment demonstrates what many mental health patients struggle and provides context 
as to the importance of focused interventions in addition to medication therapy options.22 
Similar to the study described above, meta-analysis of schizophrenic patients found that 
non-adherence primarily stemmed from a lack of understanding, medication beliefs and 
substance abuse. In these patient populations, this nonadherence also led to increased risk 
of relapse, increased hospitalizations and suicide. 23 Patients who exhibited increased 
adherence also had better relationships with their healthcare staff as well as a better 
overall understanding of the medication benefits.23  
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Bone Marrow Transplantation and the Impact on Mental Health 
  Bone marrow transplant (BMT), also known as hematopoietic stem cell 
transplants (HSCT), is primarily used for the treatment of hematological malignancies.24 
The process includes introducing healthy hematopoietic stem cells (usually collected 
from the bone marrow) into a patient after eradication of the patient’s own bone marrow 
through irradiation and chemotherapy.25 A BMT is either allogeneic or autologous. 
Autologous transplants collect, purify and re-introduce the primary patient’s own cells 
back into the body. Allogeneic transplants utilize donors who have matching human 
leukocyte antigens (HLA), which generally may include a matched family member, 
unrelated matched donor, or a family member with mismatched alleles referred to as 
haploidentical (more rare and higher likelihood for post-treatment difficulties).25 The 
result of an allogeneic transplant is that an entirely new immune system is established by 
the donor stem cells. 
  BMT therapy has many complications due to its rigorous process. Regardless of 
the type of BMT, this “survival treatment” includes chemotherapy, irradiation and the 
long-term period of isolation in a germ-free unit. Complications can range from 
neutropenia, sinusoidal obstruction syndrome (SOS), and mucositis, to graft versus host 
disease (GVHD) and death. Additionally, these complications following therapy may be 
acute (within 90 days) or chronic (greater than 90 days). A 2010 study found that 
approximately 30% of patients survived five years after BMT. Those who did survive 
five years, however, had an additional 15-year survival rate of 80%.26 Most mortality, 
however, is a result of the underlying malignancy and not the BMT itself. 
  Because our objective was to determine whether genetic factors of the immune 
system have a role in psychiatric pathophysiology, the fact that BMT can itself impact 
psychiatric disorders, primarily due to trauma associated with the therapy, is a 
complication of our design. One study showed that approximately 40% of BMT patients 
develop a clinically significant psychopathological disorder.27 The study assessed the 
process of BMT and the potential induction of mental health disorders on both non-
diagnosed and previously diagnosed mental health patients due to the physical and 
psychological stress that is exerted throughout the treatment. The two primary disorders 
induced or exacerbated were depression and anxiety. These cases, however, were mostly 
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in patients who had a relapse of their cancer following their BMT, or in those receiving 
chronic prednisone therapy.27 Though the study seemed to show a large portion of 
patients with this concern, further investigation revealed it to be more concentrated in a 
patient population with these specific complications. Additionally, most patients resolved 
from the associated symptoms within 2-3 months post-BMT, thereby not leading to the 
requirement of a chronic mental health diagnosis.3  
 BMT has also been postulated to cause post-traumatic stress disorder (PTSD), 
depression, and anxiety. In a single-center study that was conducted in 37 female patients 
that were newly diagnosed with breast cancer, patients were assessed for the incidence of 
anxiety, depression or PTSD, and when it occurred during their cancer progression and 
treatment timeline.28 The study used a symptom assessment scale, the Profile of Mood 
States (POMS), which includes multiple psychiatric conditions, though focusing on 
PTSD. One group of breast cancer patients underwent BMT following chemotherapy and 
was compared to a secondary group that only received chemotherapy and/or surgical 
interventions. Patients underwent the evaluation at initial diagnosis, initial treatment, 
recurrence of cancer (if applicable), BMT (if applicable) and at follow-up visits at 3, 6 
and 12 months.28 Incidence of PTSD was comparable among groups at time of diagnosis, 
and temporary phases of anxiety and/or depression were noted to occur throughout 
treatment. The patients who underwent BMT did not have higher rates of any symptoms 
except for a slightly elevated confusion score. Although this study had a smaller patient 
population, it provides an analysis of the impact of cancer on mental health distress, and 
that these outcomes are not significantly impact by BMT therapy.28  
In recent years, healthcare teams have begun to assess patients’ mental health 
state prior to BMT to assess their overall wellness and a patient’s ability to successfully 
complete such a rigorous therapy. Many oncology teams utilize the National Cancer 
Center Network (NCCN) distress thermometer (DT) prior to BMT to evaluate a patient’s 
stress level and ability to cope with such a procedure. 29 In a single-center study, 50 
patients were assessed for mental distress prior to their BMT therapy. These patients were 
assessed using the NCCN DT, the Hospital Anxiety and Depression Scale (HADS), and 
the Coordinating Rating Scale (CRS) to assess patients’ readiness for BMT. 29 This study 
found that 51% of patients had a statistically significant distress level of anxiety or 
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depression. The study also found that healthcare professionals underestimated the number 
of patients struggling with depression and/or anxiety associated with BMT.29 
 Because patients diagnosed with psychiatric conditions struggle with adherence, 
there is concern in whether or not patients with psychiatric diagnoses are able to 
effectively complete BMT therapy. One previous study was conducted to determine what 
the general effects of BMT were on patients that had a prior psychiatric diagnosis.24 The 
study followed seven patients with leukemia who were also previously diagnosed with 
psychiatric conditions ranging from bipolar mood disorders and autism spectrum disorder 
to schizophrenia and borderline personality disorder. Of the seven patients, all were able 
to complete treatment with the exception of one patient diagnosed with borderline 
personality disorder. All others were able to successfully complete the BMT treatment 
with little to no adverse effects related to their psychiatric illness.24 It was found that 
patient comprehension, proper psychotherapy before, during and following treatment and 
proper pharmacotherapy led to positive results with minimal adverse psychiatric effects. 
Additional studies noted that BMT in borderline personality patients was difficult to 
complete.30 Treatment failure seems to be associated with the patient’s ability to first 
comprehend the treatment, but then later exhibit changes in comprehension or acceptance 
of the treatment plan as their thought processes cycle between multiple personalities. The 
patient’s physical and emotional wellness, however, is not typically hindered by the 
process of BMT induction, treatment, or follow-up.24  
  In summary, BMT can provide positive outcomes for those with or without prior 
psychiatric diagnoses. The BMT process induces minimal adverse effects related to 
psychiatric conditions.24 As we use medication adherence measurements as a determinant 
of psychiatric disorder severity and response, it is important to consider these previous 
studies and characteristics of the impact of BMT itself on the mental illness. 
 
Hoxb8, Microglia and Potential Mechanistic Explanations 
 Studies using mouse models have assessed a specific genetic variant that may 
contribute to changes in the immune system that could be associated with psychiatric 
conditions. The gene components most studied is the Hox gene group and 
specifically Hoxb8 (OMIM *142963).4,31 The Hox genes primarily function to provide 
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positional values in axes of the embryo, aiding in development. The protein encoded by 
Hoxb8 is involved in the differentiation of myeloid progenitor cells into microglia for 
functions within the brainstem.4 
  Microglia function as the immune cells of the brain, having multiple purposes 
within the central nervous system. They act as macrophages by regulating foreign bodies 
access, responding to invasive pathogens by phagocytosing and killing them, and 
initiating inflammatory responses to infection and other traumatic processes.22 The 
microglia also assist as dynamic contacts with synapses and may represent a stabilization 
and management system for neuronal cells.4 When the number of microglia is decreased 
in the brainstem, the corticostriatal circuit is affected, causing abnormalities including 
frontal cortical synaptic expansion and striatal synaptic contraction. These changes lead 
to problems such as excess dendritic spines, pre-and post-synaptic structural changes, and 
long-term potentiation defects.32 Deficits primarily seen with structural changes to 
synapses and dendritic spines involved decreased neurocognitive functioning similar to 
those who suffer from Alzheimer’s disease, sever schizophrenia and/or autism spectrum 
disorder.33     
 Mutation of Hoxb8 that inhibits functional protein production in mice induces an 
OCD-like behavioral phenotype. The two primary mutations of note at this time are a 
nonsense mutation of the first exon and a frameshift mutation in a premature translation 
stop codon that could lead to the complete alteration or removal of Hoxb8.3 Mice that 
lack Hoxb8 display uncontrollable grooming of not only the individual mouse but also of 
its cage mates. This behavior is thought to be due to a potential change in cognitive 
function as well as the loss of spinal cord sensory function.4 These mutant mice were 
observed to spend an average of one hour less sleeping than the control group to focus on 
grooming, leading to excessive hair removal and skin lesions.3 In addition to excessive 
grooming, these mice also exhibited hyper-anxiety and social behavior issues. Symptoms 
were difficult to resolve. In one study, knock-out mice were treated with fluoxetine, a 
selective-serotonin reuptake inhibitor indicated for the treatment of depression and OCD. 
The drug provided a resolution of the hyper-anxiety and social behavior issues but did not 
impact the excessive grooming behavior.27 The study led investigators to hypothesize that 
the absence of functional Hoxb8 was associated with obsessive compulsive behaviors. 
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Through further studies of Hoxb8 deficiencies and its effect on OCD tendencies in 
mice, it was found that the only way excessive grooming behaviors could be reversed is 
through a bone marrow transplant from a healthy mouse.4 This adoptive transfer of 
normal bone marrow to rescue Hoxb8 function and eliminate OCD tendencies shows the 
potential pathologic involvement of immune function associated with OCD. Therefore, it 
is hypothesized that other psychiatric conditions may also be affected by the immune 
system and that a change in said function through BMT could alter psychiatric 
conditions.  
  Since activity was noted in the central nervous system, researchers then wanted to 
determine whether Hoxb8 had a role in affecting nociceptive (pain) receptors and 
cognitive function in addition to the impact on behavioral.34 A study analyzed knock-out 
mice that had healthy Hoxb8 removed in order to then see if both spinal cord function as 
well as induced OCD tendencies would be reversed.4 They found that when 
the Hoxb8 gene was removed only from the hematopoietic system, it led to excessive 
grooming but no spinal cord sensory defects.4 Investigators then re-introduced healthy 
Hoxb8 genes into the mice. This led to hair regrowth on the previously exhibiting 
excessive grooming mice over five months, with four of the ten mice making a full 
recovery and becoming indistinguishable from the wild-type mice.4 
 These studies help to differentiate behavioral symptoms from pain pathways and 
also pinpoint the hematopoietic system as an area of intervention to improve behavioral 
symptoms, but unable to restore cognitive function.4 A secondary study also reviewed 
this theory and found that knock-out mice with mutated Hoxb8 showed no skeletal, 
forearm clasping or dorsal root ganglia defects leading to a focus on the treatment of 
behavioral changes for the mice.3 Consequently, BMT produced some positive outcomes 
such as the reversal of excessive grooming behaviors. Nociceptive and spinal cord 
defects, however, were not able to be reversed if observed prior to transplant.  
  Additionally, some researchers have hypothesized that the Hoxb8 gene is only 
involved in the embryonic phase of life, with no involvement in adult species. RT-PCR 
assays, however, confirmed that the Hoxb8 gene was not only expressed in embryonic 
development but also in adult mice.27 In adult mice, the effects of Hoxb8 were further 
analyzed through functional imaging studies to determine where in the brain may be 
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associated with changes in Hoxb8. The results showed that Hoxb8 was present in the 
basal ganglia and neocortex, which are primarily involved in the OCD circuit of the brain 
function.3 These results associate Hoxb8 gene expression and behavior issues in mice and 
suggests a potential association with human trichotillomania or OCD. 
  When reviewing these studies, it is valuable to understand the similarities and 
differences of OCD and trichotillomania (TTM). Trichotillomania is primarily known as 
repetitive hair-pulling that leads to noticeable hair loss.35 This repetition is due to an 
uncontrollable urge and instant gratification associated with impulsivity, whereas OCD is 
more focused on obsessive thoughts that lead to ritualistic behaviors.35 Though the two 
are similar in regards to symptomatology, it was found that OCD has a much higher 
incidence of lifetime disability whereas TTM may be managed over a shorter period of 
time. Additionally, TTM has a lower response rate to treatment which makes the disease 
more difficult to evaluate by examining medication use.35 In the studies described above, 
the primary diagnosis observed in mouse models was obsessive-compulsive disorder, 
although components of TTM were acknowledged and considered on the spectrum of 
OCD.31 
 
Case Reports 
 The studies conducted in animals described above provide compelling evidence 
that genetic mutations in immune genes could be associated with psychiatric illness. 
However, no controlled trials exist that address this hypothesis in humans. Data is limited 
to a case series and a few case studies that provide anecdotal support. A study is being 
conducted in which investigators have requested records from cases involving BMT and 
coincident schizophrenia. Thus far, they have collected data for 22 patients over the 
course of 15 years with schizophrenia prior to BMT that also had an autoimmune 
diagnosis.36 For the patients currently included, the post-BMT results included reduced 
symptoms associated with both schizophrenia and their autoimmune diseases. The 
reduction of symptoms is being assessed through reviewing treatment use, which 
decreased for all patients following their BMT procedure.36 This study has laid the 
groundwork to assess more patients diagnosed with psychiatric conditions undergoing 
BMTs and in order to evaluate its impact on long-term outcomes.  
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  There is little to no information regarding patients undergoing a BMT and having 
reversal of symptoms associated with their psychiatric diagnosis. The only documented 
incident of this phenomenon took place in 2009. A treatment-resistant schizophrenic 
patient underwent a BMT to treat acute myeloid leukemia.37 Before his BMT procedure, 
the patient’s treatment regimen included quetiapine, risperidone, and olanzapine. The 
patient suffered from delusions and hallucinations that continued to be refractory to these 
therapies. He was deemed appropriate for BMT as a part of his AML treatment and went 
through 34-day isolation and had a rigorous follow-up treatment including methotrexate, 
cyclosporine, and tacrolimus to help avoid GVHD.37 The patient completed the BMT and 
all additional treatment with little to no complications, including no adverse impact on his 
mental health status. Following his allogeneic BMT procedure, the patient no longer 
required antipsychotic therapy, had a decrease in his positive and negative symptoms 
scale (Positive and Negative Symptom Scale - PANSS) score, and an increase in his 
score on the overall functioning scale (Global Assessment of Functioning Scale - GAF).38 
Even eight years post-BMT, he still showed a resolution of symptoms with no mental 
health medication or intensive treatment required.37 Figure 1.1 summarizes his psychiatric 
disposition both prior and following his BMT procedure.  
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Table 1. 4 Treatment from Case Report for 24-year-old Schizophrenic Patient Who 
Underwent BMT37  
 
 There is also a case report of a patient experiencing the induction of psychiatric 
symptoms following BMT. A letter to the editor of Bone Marrow Transplant describes 
the case of a 67-year-old patient with no prior history of psychiatric illness who received 
a BMT for the treatment of with chronic lymphocytic leukemia (CLL) and bone marrow 
aplasia, requiring weekly blood transfusions.39 He received bone marrow donated by his 
brother, who was clinically diagnosed with schizophrenia. Following the transplant, the 
patient began to complain of frequent hallucinations, bizarre delusions and thought 
broadcasting with clear consciousness. Although he had complete hematologic recovery, 
he was unable to be successfully treated for his recent onset psychiatric condition. 
Risperidone, citalopram, and haloperidol were all administered without success, leading 
the family to provide comfort care for the patient, who was then lost to follow-up.40 The 
 Before BMT After BMT            Interpretation 
Medications taken 
Quetiapine 800mg/day 
Risperidone 12mg/day 
Olanzapine 20mg/day 
None   
PANSS -Total score16 From 90-110 Approx. 30  
Lowest: 24  
(No 
symptoms 
present) 
Highest: 168  
(Extremely  
severe symptoms) 
GAF - Total score17 Down to 20 Approx. up to 95 
Lowest: 1 
(Considered 
suicidal 
and/or 
homicidal) 
Highest: 100 
(Function in a  
positive manner  
in their daily life) 
Primary symptoms  Hallucinations Delusions None   
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patient later died due to unknown causes. The primary theory that was considered in this 
report was that of the adoptive transfer of schizophrenia from the brother. While 
anecdotal, these cases provide evidence of a potential link between schizophrenia and 
immunity. 
 
GWAS and Potential Mechanistic Explanations 
 Over the past decade, researchers have begun to examine genomic data in order to 
evaluate the impact of common genetic variations on human health.41 The process of 
genome-wide associated study (GWAS) utilizes experimental genomic databases that 
allow investigators to study the associations between single-nucleotide polymorphisms 
(SNPs) and characteristics of disease.42 The prevalence of SNPs are compared between 
subjects with a history of a diagnosis versus a control population to determine whether an 
association exists.43 
 Genes are the small hereditary components that make each human unique by 
comprising the chromosome. Genes are made of deoxyribonucleic acid (DNA) and 
provide both structural (genotypic) and physical (phenotypic) characteristics.44 On each 
chromosome, there are specific locations referred to as locus (or loci) that contain the one 
or more specific genes.45 These loci are utilized as markers of specific locations, 
especially when certain genetic mutations are being studied and attempted to be located 
through genome mapping.45 
 There are multiple factors that determine the extent to which a GWAS is 
successful. These factors include (1) the number of loci affecting the trait in the effected 
population, (2) the distribution of these loci’s allele frequency (called genetic 
architecture), (3) the sample size, (4) the genome-wide database used in the GWAS and 
(5) how heterogeneous the trait and/or disease is.46 This provides context for how to 
evaluate these studies, which is critical because there are extremely specific evaluations 
that differ from one study to the next.  
 GWAS initially evaluated the genomic characterization of common conditions 
including type-2 diabetes and autoimmunity, but slowly has increased to include 
psychiatric conditions. The psychiatric data has now been refined into a secondary 
database called the Psychiatric Genomics Consortium (PGC).47 There are over 900 
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investigators from 40 countries that have contributed to the PGC network which includes 
more than 400,000 human participants.48 The mental health disorders included in this 
database are anxiety disorders, major depressive disorder (MDD), manic depressive 
disorder (bipolar), schizophrenia, suicide attempts, and substance use disorders. 
Investigators are currently expanding the PGC to also include anorexia nervosa (AN), 
autism, OCD/Tourette’s syndrome and PTSD.48  
 The primary psychiatric diagnosis that has been reviewed through GWASs is 
schizophrenia. Schizophrenia is noted to have a high heritability of approximately 64-
81%.47 In 2009, this was first reviewed to find 3,000 cases linked to a specific genomic 
locus that then grew to include over 35,000 cases in 2014.43 This study also found 108 
risk loci associated with schizophrenia that affects enhancers in the brain and immune 
tissues.49 More specifically, these SNPs linked with schizophrenia were also associated 
with glutamatergic transmission, calcium channels and potential changes in 
immunomodulation.43 These results continue to support the likelihood that immune 
function plays a specific role on psychiatric conditions, especially those affected by 
cognitive function impairment—autism spectrum disorder, Alzheimer’s disease, and/or 
schizophrenia. 
 A secondary study has identified additional gene SNPs that are enriched in 
patients diagnosed with schizophrenia. A case found a cross-phenotypic link between 
schizophrenia and different metabolic processes. The SNP primarily involved was 
rs13107325-T and the metabolic processes included were body mass index (BMI), high 
density lipoprotein (HDL) cholesterol, blood pressure and N-terminal pro b-type 
natriuretic peptide in the acute coronary syndrome.49 These findings introduced the idea 
that not only could schizophrenia and/or other mental health conditions may be 
associated with immune function changes, but potentially metabolic function could also 
be associated with mental health conditions. In addition to this specific SNP associated 
with metabolic processes and schizophrenia, patients with this SNP also had an increased 
likelihood to have cardiovascular disease, lung cancer and bipolar disorder, meaning that 
this specific SNP could be associated with a wide variety of conditions that scientists 
would have not previously associated with one another, although the association between 
schizophrenia and bipolar disorder were not statistically significant.   
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 There are no specific genes that have been associated with being diagnosed with a 
specific psychiatric condition, but more SNPs are being identified each day that may play 
a role in how patients develop symptoms. The process of identifying mutations and 
genetic components associated with psychiatric conditions will continue to evolve over 
time, but it does provide a potential framework for future research to study more specific 
genes (like Hoxb8). These GWASs could lead to additional treatment options that are 
more patient specific instead of the iterative model currently being utilized to allow 
mental health patients to find their optimal therapy. Additionally, these GWASs could 
also lead to the discovery of new therapeutic targets which could provide better patient-
specific therapies.42 
 
Summary  
 These studies define a potential association between psychiatric conditions and an 
immune-related mechanism that may, in turn, provide a therapeutic target for select 
patients. The purpose of this thesis is to better understand the potential role of immunity 
in the pathogenesis of psychiatric conditions.  Although multiple theories regarding the 
mechanisms of immune system influence in mental health pathology to our knowledge 
medication use before and after BMT has not been studied. This connection has not been 
previously reviewed using a large-scale population. We hypothesize that there is a 
measurable relationship between BMT and the induction and/or reversal of psychiatric 
pathology. 
 Our study utilized medication use and adherence as a surrogate to measure the 
severity of psychiatric illness. We chose to utilize medication use, specifically through 
medication possession ratios (MPR) and proportion of days covered (PDC), because it 
provided an analysis of patients’ treatment over time. The reversal of psychiatric 
diagnoses in patient medical records is rare, so utilizing medication use provided a 
method to monitor a patients’ symptoms, rather than an objective removal of a diagnosis. 
By comparing medication use before and after BMT in patient populations with 
previously diagnosed psychiatric disorders, we were able to generate results that support 
the scientific premise that an immune component may exist to pathologies that alter 
mental health. 
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Section Two: Methods 
Overview 
 We conducted a retrospective cohort study that compared the use of psychiatric 
and pain management medications used in the treatment of psychiatric diagnoses before 
and after BMT. This study was classified as a quasi-experimental design due to our study 
population including both those participating as well as others not participating and using 
an additional medication group for overall comparison. We utilized pre-BMT and post-
BMT treatment timeframes and evaluated medications by medication class through 
generic product identifier (GPI) and Medispan database codes. Medication classes being 
reviewed include those specific to psychiatric diagnoses and pain management. 
Antihypertensives were included as a non-psychiatric control class. Antihypertensive 
medications were determined appropriate for our control because they are a common 
medication class that manage a lifelong diagnosis with discontinuation of use being rare. 
As such, two primary analysis groups were identified through generic product identifier 
(GPI) codes: psychiatric and pain management medication use (exposed) and 
antihypertensive medication use (unexposed). We used adherence rates, in the form of 
medication possession ratios (MPR) and proportion of days covered (PDC), to evaluate 
the utilization changes in each medication group to measure the effects of BMT on a 
patient’s medication management of their primary diagnoses. 
  
Study Population 
 Enrollees were included in this study if they were 18 years of age or older, had a 
defined psychiatric disorder, received an allogeneic BMT (both matched sibling and 
unmatched donors included), and filled outpatient psychiatric or pain management 
prescriptions within two years before or after the BMT. Conditions studied included 
bipolar/manic and major depressive disorder, obsessive-compulsive disorder, general 
anxiety disorder, schizophrenia, suicide attempts, psycho-active substance abuse, opioid-
related disorders, post-traumatic stress disorder, panic disorder, alcohol-related disorder, 
and movement disorders. Diagnostic codes specified by the International Classification of 
Diseases, versions 9 and 10, are listed in Appendix A.48,49 Figure 2.1 provides a timeline 
for data selection. 
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Figure 2. 1 Timeline for Sample Selection and Eligibility Requirements 
 
 
 
 Patients were excluded from this study if they were under the age of 18, if they 
received an autologous bone marrow transplant, were diagnosed with epileptic disorders 
through ICD-9 or -10 codes, or if the patient had no final PDC reported following the 
intervention (due to change in payer or death). Patients that received an autologous BMT 
were excluded since this procedure involves harvesting the patient’s own stem cells and 
then re-introducing them. Though the immune system is repaired, it still contains the 
original genetic components, nullifying any potential induction or reversal of a 
psychiatric condition due to a new immune system. Patients with epilepsy have 
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medications that overlap with those used to treat manic depression and therefore may 
skew the results.50 
 Data was gathered from the Truven Health MarketScan® Research Database and 
included patients enrolled in health plans between January 2009 and December 2016 with 
medications being reviewed if they were filled within two years before or after the BMT 
index date.51 We collected medical and prescription claims through this database from 
nearly 350 private payers. This database included patients that were de-identified and 
anonymous. Therefore, the study did not meet the federal definition of human subjects 
research, exempting it from IRB approval.52 Additionally, medication identifiers were 
collected from the Medi-Span® network and utilized GPI codes for group 
classifications.53 Appendix B provides specific codes used throughout the study.  Figure 
2.2 provides a flow diagram of the subject selection process for our patients and the 
medications reviewed.  
 
Figure 2. 2 Study Population 
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Exposure and Outcomes 
 The quasi-experimental design provided a method to analyze and review the 
utilization rates before and after BMT for our primary association medication classes and 
a non-related medication class (antihypertensives). Exposed subjects were those that were 
treated with prescriptions for psychiatric conditions and/or pain management while those 
unexposed were classified as those with prescriptions for antihypertensive medications. 
Patients with both exposed and unexposed groups are included in this study since the 
primary focus was the relationship and analysis between pre- and post-BMT rather than 
differences between medication classes.  
 The primary outcome was to compare total PDCs before and after BMT per 
patient for each medication class. This analysis was completed for each medication group 
including the exposed and unexposed medication groups. Furthermore, PDC ratios 
(before/after and after/before) were calculated and graphed for each patient in order to 
visualize overall trends and pinpoint patients that experienced either a dramatic increase 
or decrease in PDC values. PDC is the recommended methodology by the Pharmacy 
Quality Alliance and CMS for estimation of medication adherence for patients using 
chronic medications.54 
 Secondary outcomes included comparison of total MPRs before and after BMT 
per patient for each medication class as well as overall MPR and PDCs categorized solely 
by medication class for summary statistics. MPR was not considered a primary outcome 
because it does not account for a maximum adherence rate due to it being a summation of 
days used rather than days covered. We decided to include it as a secondary measurement 
to show the basis of what led us to utilize PDC. Although overall MPR and PDC per 
medication class does not provide an accurate assessment of change per patient, it 
provides a baseline review of medication change regardless of individual patients. This 
initial analysis provided an understanding to warrant additional research on a per patient 
level for medication classes before and after BMT.  
In order to calculate a total MPR and PDC per patient, we performed a summation 
of the individual MPRs and PDCs for each patient in each medication class. This 
summation enabled us to calculate a more accurate total MPR and PDC than taking a 
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mean value by averaging the individual medication MPRs and PDCs per patient. The 
total MPRs and PDCs before and after were compared with a paired t-test. 
 MPR was defined as the total number of days that a medication was dispensed by 
the pharmacy to each patient, divided by the patient’s total follow up time in days, up to 
two years pre- and post-BMT. Furthermore, this was calculated as the difference between 
the last and first prescription date plus the supplied days of the last prescription.55 
Although MPR can adequately find baseline information for a patient’s medication 
adherence, it does not have an appropriate maximum, resulting in the ability for 
adherence to be greater than 100%. This is because MPR includes all similar medications 
in the numerator, therefore having overlapping medications which may contribute to 
overestimating the patient’s MPR, or adherence. 
 Due to this limitation, we decided to also find the PDC which accounts for this 
overestimated adherence concern. Figures 2.3 and 2.4 show the equations for both 
adherence measurements. PDC was defined as the proportion of days in the measurement 
period “covered” by prescription claims for the same medication or another in its 
therapeutic category.56 The primary difference between each analysis is that PDC only 
considers days that the patient is covered during a specific time rather than a summation 
of all days during the medication period. This provided a method to account for multiple 
medication regimens as well as made it impossible to calculate an adherence greater than 
100%.57 
 
Figure 2. 3 Equation representing MPR57 
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Figure 2. 4 Equation representing PDC57 
 
 
 
Confounders 
 Allogeneic BMT is generally reserved as a secondary treatment options, for 
hematologic cancers and long-term remission opportunities. For many patients, this 
means that they are generally more ill than our general population and may have multiple 
chronic conditions. This can lead to decreased quality of life, increased polypharmacy, 
and increased medication use. Consequently, the disease burden was determined using 
the Charlson Comorbidity Index score and individual components that were then 
reviewed as our primary descriptive characteristics.58 Of note, subject characteristics 
including sex, gender, and age, were not identified through Truven’s database and are 
discussed further in the limitations section later in this paper. 
 An acceptable percentage for adherence in most chronic disease states is generally 
around 0.8 (80%).59 Those with major psychiatric diagnoses, however, suffer from 
debilitating illness and a lack of motivation due to adverse effects and impaired cognitive 
function, leading to a decreased adherence approximately being 0.5-0.6 (50-60%) with 
certain conditions, like schizophrenia, having an adherence of approximately  0.35 
(35%).60 Consequently, we considered ≥ 0.5 (50%) to be an adherent patient for our study 
while those < 0.2 (20%) being considered as having a low adherence (potentially 
considered a discontinuation of the medication) when assessing their final PDC and MPR 
values.  
  
Statistical Analysis 
 Descriptive statistics were determined for patient comorbidities using the 
Charlson Comorbidities Index and frequencies were assessed for these conditions among 
the population. Summary statistics were calculated for each medication class. The 
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difference in overall number of prescriptions was examined. Additionally, the mean 
MPRs and PDCs before and after BMT per medication class were also determined and 
included in summary statistics. 
 Analysis of the total PDCs and MPRs per patient for each medication class before 
and after BMT was conducted using paired t-tests. Confidence intervals were also 
reported for MPR and PDC for each medication class per patient. These 95% confidence 
intervals are defined as the range that the actual mean value lies within 95% confidence 
and at a statistical significance level of 0.05. Q-Q plots were used to asses normal 
distribution. Bivariable analyses used non-parametric testing strategies such as the 
Kruskall-Wallis test to measure the effect of each adherence variable comparing results 
before and after each patient’s BMT. The Dunn test was utilized to account for multiple 
comparisons for values of statistical significance.  
 A two-tailed analysis and paired t-tests were completed with statistical 
significance defined at a p-value < 0.05. All data analysis was completed using SPSS 
Version 26.0.61 This study’s data represents proprietary information used for research by 
the Institute for Pharmaceutical Outcomes and Policy at the University of Kentucky 
College of Pharmacy.  
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Section Three: Results 
Study Population 
 The study population that was obtained through the Truven Health MarketScan® 
Research Database and the method used to apply inclusion criteria are depicted in Figure 
3.1. The final group for analysis included 8,233 patients who had a psychiatric diagnosis, 
underwent BMT, and received medication for treatment of a psychiatric condition within 
2 years. The number of prescriptions for the treatment of each condition, along with the 
number of prescriptions for antihypertensives in these patients, are listed below. 
 
Figure 3. 1 Subject Selection Process 
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Figure 3.1 Subject Selection Process (Continued) 
 
 
 
 In addition to the prescriptions patients received, we also assessed the frequency 
and percentages of comorbidities for our patient population through analysis of Charlson 
Comorbidity Index in Medispan. These results are listed in Table 3.1. This table reflected 
what was anticipated to be the most likely comorbidity in the patient population (cancer). 
It was surprising, however, that more patients than 81.6% did not have a cancer diagnosis 
since BMT is generally only utilized post-chemotherapy associated with cancer. 
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Table 3. 1 Comorbidities Frequencies and Percentages 
 
 
 
Descriptive Analysis  
 To determine the effect of BMT on psychiatric medication utilization, medication 
adherence PDC was used as a primary outcome, with MPR used as a secondary outcome. 
Both MPR and PDC were included because they each are associated with different 
limitations.  
 MPR was calculated by taking the sum of all medication days’ supply filled 
divided by the total days in the period. As discussed in the Methods section, this may 
skew the results to overestimate the MPR and ultimately, a patient’s adherence rate, due 
to the fact that there is not a maximum number for the ratio when patients receive 
multiple medications for the treatment of a diagnosis. In order to minimize 
overestimation, MPRs included in this study were limited to a maximum ratio of 5.62 
PDC, however, eliminates this issue by having a natural maximum of one. PDC measures 
the portion of days covered in a given time period by at least 1 medication to treat that 
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diagnosis rather than a total days supplied of all medications that may have overlapped 
for that same period. 
 The changes in total before and after prescription count per medication class were 
calculated for the data sets. The number of prescriptions received by patients, grouped by 
medication class, are presented in Table 3.2 (MPR) and Table 3.3 (PDC). 
 
Table 3. 2 Number of Prescriptions Prior and Following BMT Used for MPR 
Calculations  
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Table 3. 3 Number of Prescriptions Prior and Following BMT Used for PDC 
Calculations  
 
 
 This data demonstrates that the total number of prescriptions in each medication 
class analyzed decreased after BMT in our patient cohort. ADHD medications, 
benzodiazepines and hypnotics/sedatives had the greatest decreases in overall 
prescriptions after BMT with mean decreases of 42%, 33% and 38% respectively. 
Between the two tables, the total prescription count is higher in each medication class for 
the MPR data since each medication is counted regardless of prescription overlap 
whereas for PDC overlapping prescriptions count as one. 
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Univariate and Bivariate Analyses 
 Table 3.4 depicts the overall change in mean MPRs calculated for each drug class 
before and after BMTs. This data is graphically represented in Figure 3.2. 
 
Figure 3. 2 Summary Statistics of Pre- and Post-BMT in Mean MPR 
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Table 3. 4 Pre- and Post-BMT in Mean MPR 
 
 
 
 Overall, the MPR values ranged from 0.17 to 0.55 with antidepressant 
medications having the largest raw difference, decreasing by 0.124. Opioids had the 
greatest percent change between pre- and post-BMT MPR at -31.6% with a raw 
difference of 0.103. Each medication class exhibited an overall decrease in MPR after the 
BMT compared to pre-BMT values.  
 MPR was also calculated for each medication class for each individual patient. 
Table 3.4 identifies trends in the overall medication class while this analysis highlights 
the changes at the individual patient level. This calculated data included evaluating the 
change in total MPR before and after BMT. In order to determine the statistical 
significance of these changes, a paired t-test was conducted since each patient had a 
before and after value to directly compare. Table 3.5 depict these results. All decreases in 
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MPR were statistically significant (p < 0.05) with all but antipsychotics being highly 
statistically significant (p < 0.001). 
 
Table 3. 5 Bivariate analysis with MPR per patient grouped by medication class as 
the outcome of interest 
 
 Figure 3.3 and Table 3.6 present mean PDC values pre- and post-BMT grouped 
by medication class while Table 3.7 contains the pertinent results of bivariate analysis of 
the PDC data analyzed for individual patients.  
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Figure 3. 3 Summary Statistics of Pre- and Post-BMT in Mean MPR 
   
Table 3. 6 Pre- and Post-BMT Mean PDC 
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 Overall, the PDC values were approximately 50% lower than the corresponding 
MPR value resulting in a range from 0.12 to 0.27. Similar to MPR, across each 
medication class, the PDC values decreased post-BMT with antidepressants again having 
the largest raw difference. Opioids, however, had the largest percentage decrease. 
Though the raw PDC values are lower than the corresponding MPR values truncating the 
raw difference between post- and pre-BMT values, the percent decrease in PDC values 
mirrors that of the MPR values. Of note, antihypertensive medications had the smallest 
percent change for both MPRs and PDCs.  
 The PDC values for each medication class when calculated on a per patient basis 
are listed in Table 3.7. P values as calculated using paired t tests, along with 95% 
confidence intervals, are included.  
 
Table 3. 7 Bivariate analysis with PDC per patient grouped by medication class as 
the outcome of interest 
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 Results for PDC per patient paralleled those from PDC of overall medication 
class. The differences were that overall fewer prescriptions were analyzed for the per 
patient group and the overall decreases were more dramatic.  
 Overall, the results presented show that MPR values provide slightly higher 
adherence rates as compared to PDC values for medication class. This is due to the 
number of prescriptions included as well as the ratio having a maximum of 5 (500%) for 
MPR as compared to PDC’s maximum being 1 (100%). Although there is a difference in 
the adherence overall, both groups showed a reduction in prescriptions and adherence for 
each medication class. These results were all statistically significant except for 
anticonvulsant medications reviewed with PDC.  
 
Event analysis for Future Studies 
 Figures 3.4 through 3.43 provide a visualization for the change in medication 
utilization for each patient before and after BMT. These scatter plots depict the spectrum 
of adherence and highlights potential outliers that may be of interest for future 
prospective and randomized controlled trials. To create these plots, the ratio of post-BMT 
and pre-BMT PDC or MPR for each patient were plotted on a linear scale.  These plots 
were included to be able to highlight the spectrum of change amongst the patients in 
order to reveal potential outliers. The before/after plots highlight those patients that 
experienced an above average decrease in MPR or PDC, while the after/before plots 
highlight patients with an above average increase in MPR and PDC. These plots provide 
evidence that there are individual patients that experienced dramatic increased or 
decreased need for a specific class of medication.  
 Figures 3.4 through 3.23 depict MPR change comparing patients with a decrease 
in medication use after compared to before BMT (Before:After) and those with an 
increase in medication use after compared to before BMT (After:Before). Table 3.8 
shows those with the largest decrease or increase (greater than 5) for MPR. 
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Figure 3. 4 and Figure 3. 5 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for ADHD MedicationsFigure 3. 6 and 
Figure 3. 7 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Anti-anxiety Medications 
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Figure 3. 8 and Figure 3. 9 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Anticonvulsant Medications 
Figure 3. 10 and Figure 3. 11 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Antidepressant Medications 
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Figure 3. 12 and Figure 3. 13 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Antipsychotic Medications 
Figure 3. 14 and Figure 3. 15 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Benzodiazepine Medications 
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Figure 3. 16 and Figure 3. 17 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Hypnotic/Sedative Medications 
Figure 3. 18 and Figure 3. 19 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Migraine Medications 
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Figure 3. 20 and Figure 3. 21  Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Opioid Medications 
Figure 3. 22 and Figure 3. 23 Scatter Plot of Pre-and Post-BMT MPR Sums per Patient for Antihypertensive Medications 
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Table 3. 8 Percentages of the Change of PDC Sums with Ratio Greater Than 5 
 
 Each scatterplot assessed the sum difference of MPR per patient organized by 
medication class. All medication classes contained outliers with ratios greater than 5 with 
those having a decrease after BMT (Before:After) having more outliers with a larger 
range of differences. This provides a visual depiction of specific outliers that could reflect 
potential change in psychiatric diagnoses due to a complete decrease in medication use.  
 Figures 3.24 through 3.43 depict PDC change comparing patients with a decrease 
in medication use after compared to before BMT (Before:After) and those with an 
increase in medication use after compared to before BMT (After:Before). Table 3.8 lists 
the percentages of each patients group with a decrease or increase (greater than 5) for 
PDC.
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Figure 3. 24 and Figure 3. 25 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for ADHD Medications 
Figure 3. 26 and Figure 3. 27 Scatter Plot of Pre- and Post-BMT PDC Sums per Patient for Anti-anxiety Medications  
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Figure 3. 28 and Figure 3. 29 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Anticonvulsant Medications 
Figure 3. 30 and Figure 3. 31 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Antidepressant Medications 
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Figure 3. 32 and Figure 3. 33 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Antipsychotic Medications 
Figure 3. 34 and Figure 3. 35 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Benzodiazepine Medications 
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Figure 3. 36 and Figure 3. 37 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Hypnotic/Sedative Medications  
Figure 3. 38 and Figure 3. 39 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Migraine Medications 
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Figure 3. 40 and Figure 3. 41 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Opioid Medications 
Figure 3. 42 and Figure 3. 43 Scatter Plot of Pre-and Post-BMT PDC Sums per Patient for Antihypertensive Medications     
Table 3. 9 Percentages of the Change of PDC Sums with Ration Greater Than 5 
 
 Each scatterplot assessed the sum difference of PDC per patient organized by 
medication class. All medication classes contained outliers with ratios greater than 5 with 
those having a decrease after BMT (Before:After) having more outliers with a larger 
range of differences. This provides a visual depiction of specific outliers that could reflect 
potential change in psychiatric diagnoses due to a complete decrease in medication use.  
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Section Four: Discussion 
Overview 
 This study is the first to analyze changes in psychiatric condition severity after 
patients undergo BMT. Medication adherence and the amount of medication needed were 
utilized to examine this potential relationship. Decreases in patient medication 
requirements after a BMT procedure may signify a resolution of psychiatric symptoms 
associated with a given diagnosis. Our results provide evidence suggesting that a reversal 
of psychiatric pathology occurs in some patients as a result of alteration of their immune 
system through BMT. This study provides novel insights concerning the potential impact 
BMT has on patients with psychiatric conditions while also providing evidence that 
supports the scientific premise encouraging further research in order to solidify the 
connection between immunologic mechanisms and long-term patient progression. 
 
Event Analysis  
 Overall, the descriptive statistics show a consistency in the reduction in the 
number of prescriptions required after BMT compared to before the procedure. Though 
this decrease does not explicitly reflect any change in patients’ psychiatric diagnoses, it 
does provide evidence that BMT has a general effect of lowering the overall number of 
prescriptions a patient requires—an indication of a potential reduction or resolution of 
psychiatric symptoms or comorbidities. The comorbidity frequencies reflect the expected 
distribution for our patient population. The majority of the patients included in the 
analysis had a recorded diagnosis of cancer, which is the primary indication for BMT. 
These comorbidity statistics reflect that the patient population analyzed is a valid sample 
to investigate the impact of BMT. For comparative note, there is no specific Charlson 
code for hypertension—the indication for our reference drug class. Therefore, there was 
no way to determine the frequency of hypertension diagnosis in our study population. 
The frequency of prescriptions of antihypertensives, however, was similar to expected 
estimates produced by general prevalence statistics. 
 Although the number of prescriptions were more numerous than initially 
anticipated, it decreased significantly when they were matched and examined at the 
individual patient level. This decrease in prescription count could be the result of frequent 
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hospitalizations that are not accounted for in the Truven database. This issue is discussed 
further in the limitations section below.  
As for overall MPR and PDC, we were able to document decreases in both values 
for each medication class, prompting our individual patient analyses. Of note, due to 
MPR having an overlap in medication use and not accounting for patients filling 
prescriptions close to their index date, the MPR analysis and data is still inflated due to a 
maximum possible ratio up to 5 (500% adherence). Though the raw numbers are more 
inflated, the before and after differences in MPR provide insight into the overall trends in 
the medication classes. MPR per patient categorized by medication class characterized a 
major decrease in use from before to after BMT. The MPR data revealed a statistically 
significant decrease in utilization for all medications, including our control group of 
antihypertensives showing a potential that cardiovascular conditions may also have a 
decrease in medication utilization following BMT.  
 PDC per patient was our primary endpoint. Overall, all medication classes had 
both a statistically significant decrease in mean PDC and in the total number of 
prescriptions after BMT, except for anticonvulsant, antipsychotics and migraine 
medications. When drawing conclusions from this data, statistical versus clinical 
significance must be considered when comparing each medication class due to our large 
sample size. Some considerations for future subgroup analyses include studies focusing 
on specific locations to be able to analyze a smaller patient population to better assess the 
clinical impact. 
 This study found that all medication classes examined had reduced use after BMT 
compared to before the procedure. Even medication classes with small decreases in use 
were noted to be statistically significant, and therefore these differences may not reflect 
clinical significance. Due to the large number of prescriptions and patients analyzed, even 
small decreases in utilization and adherence were highly statistically significant. In order 
to determine clinical significance, more detailed analysis of individual patients that had 
extreme changes in medication use, as reflected in the upper regions of the respective 
scatter plots, could be performed. Through further review, statistical versus clinical 
significance should be considered, as investigation of additional confounders could be 
accounted for in order to produce a more accurate assessment and improve our ability to 
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gauge the clinical significance of the results. 
 Secondary analyses included in the study were the MPR per patient and PDC per 
patient scatter plots that measured the difference ratio of after to before medication use 
for each patient. These plots were included to highlight the spectrum of change amongst 
the patients in order to reveal potential outliers. The before/after plots highlight those 
patients that experienced major decreases in MPR or PDC while the after/before plots 
highlight patients with major increase in MPR or PDC. These plots demonstrate that there 
were individual patients that had dramatic decrease or increase in medication 
requirements for specific medication classes. These dramatic changes in MPR and PDC 
signify that a subpopulation of patients had resolution of symptoms and a reversal of a 
psychiatric illness. The percentage of patients that were included in the extreme group of 
a decreased need for medication was consistently higher than the percentage that 
experienced an extreme increase in medication use (Table 3.9). This is consistent with 
our hypothesis that psychiatric pathology is partly driven by genetic alterations of the 
immune response. It stands to reason that, because all patients included in the analysis 
had a pre-existing psychiatric diagnosis, if polymorphisms associated with immune genes 
contribute to this pathology, the balance of overall medication use would be shifted 
downward. 
     This indicates that there is a need for more research to be completed, either through 
randomized controlled trials or prospective analysis. These potential studies would 
provide additional insight into the relationship between the immune system and 
psychiatric pathology driven by genetic factors. This initial medication analysis only 
provides an overview of an association between BMT and psychiatric diagnoses. 
Prospective patient tracking would enable more detailed follow up with the ability to 
monitor changes in patient diagnoses directly.  
 Our control medication class, antihypertensives, had similar results to the 
medication classes of interest. It is noteworthy that the antihypertensive class had the 
smallest percentage change for overall MPR and PDC, as well as PDC calculated on a per 
patient basis. This could mean that although the decrease in antihypertensives required 
post BMT was statistically different, the change in medication requirement induced by 
BMT was minor comparatively speaking. Alternatively, a previously identified link 
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between schizophrenia and hypertension could account for this result.  In the 
schizophrenia GWAS study discussed previously, patients diagnosed with schizophrenia 
that carried polymorphisms in a specific gene locus were found to also have an 
association to an adverse effect on cardiovascular health.49 This analysis is still being 
conducted, but could provide further correlation of the unknown effects of our immune 
system and the role it plays in multiple diseases including psychiatric and cardiovascular 
illness.  
 
Strengths  
 Most research has focused on mouse models or GWAS studies gathering baseline 
knowledge rather than applying it to clinical practice. Additional information is focused 
on humans through case reports rather than specific analysis of patient factors. This 
project is the first study to explore the impact of BMT on psychiatric conditions at the 
patient population level using medication adherence and utilization analysis. This study is 
a first attempt at systematically connecting BMT to psychiatric condition resolution/onset 
in a human population. Previous reports focus on anecdotal evidence on a case-by-case 
basis. This study provides the first population analysis associating BMT with decreases in 
psychiatric medication use and adherence.  
 This study design of reviewing medication adherence is also one that has not been 
utilized in the past in regard to this patient population. Medication use, although it may 
not encompass the overall impact of BMT on the changes in psychiatric disease severity 
or progression, provides a baseline analysis for how treatment of these conditions is 
impacted. The study provided an overall understanding of the changes in therapy for 
patients adjusting to medication requirements after BMT therapy, and the potential 
change in psychiatric symptoms and/or diagnoses—providing an impetus for further 
investigation. The overall decrease in medication use reveals that BMT has at a minimum 
an impact on prescription number and medication requirement while still prompting 
further investigation into the effect it has on actual diagnostic outcomes.  
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Limitations 
 With regard to descriptive statistics, our data did not include age, sex or ethnicity 
of the patients analyzed in this cohort. Utilizing this information could have helped to 
provide secondary analysis that may lead to certain patient characteristics having an 
association with medication use reduction. In future studies, this information could also 
be analyzed and provide additional data that may pertain to the direct impact of BMT on 
psychiatric conditions depending on patient factors rather than medication use.  
 With both MPR and PDC, adjustments in a patient’s dose was unaccounted for in 
this study. For patients with mental health conditions, both individual therapies and 
medications dosage may be adjusted frequently since psychiatric diagnoses generally 
require frequent alterations to optimize the appropriate individualized therapy. Although 
medications within the same drug class and the number of days that a medication was 
prescribed were accounted for through this study, an individual’s dosage adjustments 
were not. This means that a discontinuation of a specific dose to switch to a different 
dose would be a change in therapy that is not captured as impacting our overall analysis. 
Analysis based on medication doses could be utilized in future studies in to order to 
provide a more complete picture.  
 Medications utilized for treating psychiatric conditions may also be used for 
similar comorbidities. For instance, we decided to exclude patients with epileptic 
diagnoses that were originally included in our analysis. Some medications used for 
epilepsy, like valproate and lamotrigine, were still included due to their therapeutic use 
for bipolar/manic depression. However, if patients also had epilepsy that was not 
formerly diagnosed, these medications could be used for that additional treatment. 
Therefore, though treatment changes may have been due to a change in a comorbid 
condition, those changes were captured as if they were due to a change in treatment for 
the psychiatric diagnosis. 
 Acute care prescriptions used while patients were hospitalized were not assessed 
or analyzed because this data was not available in the databases utilized. Because of the 
multiple comorbidities within our study population, and because of the high likelihood of 
hospitalization in a subset of patients for the treatment of their psychiatric conditions, 
periods of hospitalization likely significantly impacted both PDC and MPR results. These 
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unaccounted hospitalizations could also help explain why the overall adherence rates 
were fairly low, even prior to BMTs. A way to account for this would be through 
hospital-specific studies that would include in-patient medications for analysis rather than 
relying solely on outpatient prescriptions.  
 A patients’ overall wellbeing and the drastic change that takes place before and 
after BMT could also be a potential reason for the decrease in medication use. Patients 
requiring this “survival treatment” may also require an extensive medication regimen due 
to the potential illness and comorbidities being treated prior to BMT. The decrease in all 
medications could coincide with a patient’s improvement in overall health and quality of 
life, thereby minimizing medication use due to becoming healthier rather than being a 
direct effect of BMT therapy.  
 Furthermore, many patients with psychiatric conditions are unable to maintain a 
steady income. In 2006, it was found that 37% of working-age adults with severe mental 
illness were uninsured for at least part of the year.63 Additionally in 2010, approximately 
33% of adults on Medicaid met the criteria for having a psychiatric condition.63 Patients 
were only included in this study if they had private insurance, which was gathered 
through our data collected from Truven Health MarketScan® Research Database.51 This 
limitation leaves a substantial portion of patients unaccounted for in our population, due 
to their inability to enroll in private insurance. This means that our results only include a 
portion of our population, rather than an adequate representation of patients with 
psychiatric diagnoses that could be further analyzed in future studies.  
 
Future Opportunities 
 This project provides a baseline understanding of whether or not there are changes 
to psychiatric illness secondary to BMT with plenty of opportunity for expansion. An 
additional model may include case studies reviewing patients previously diagnosed with 
psychiatric conditions undergoing BMT and the potential long-term effects that took 
place as a result. The previously mentioned study with only seven patients is the only 
case study article addressing this issue at this time. Prospective studies should be 
designed to investigate changes in diagnosis and/or symptoms of psychiatric conditions 
for patients undergoing BMT. However, prospective studies in humans are fraught with 
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difficulties, including those that are conducted in the challenging population of patients 
with psychiatric conditions. Our data provides additional evidence of a link between 
immunity and psychiatric illness, and therefore future clinical studies are warranted, as 
most of this work has been in animal models.  
 In addition to medications, investigators could also consider examining patient 
assessment scores and the changes before and after BMT. These could include PANSS 
and GAF that were utilized in a case report above as well as Daily Assessment 
of Symptoms – Anxiety, Generalized Anxiety Disorder 7 (GAD-7), Hamilton 
Anxiety Scale (HAM-A), Panic and Agoraphobia Scale (PAS) and others.17 These 
diverse scales provide different ways to assess symptom management that may not be 
addressed through medication utilization. Medication utilization only directly provides 
information regarding changes in therapy while these scoring systems measure patients’ 
symptoms. These could be used in the future to generate additional support for the link as 
well as provide an explicit link between BMT and resolution of psychiatric conditions. 
 
Conclusions 
 Overall, the results indicate a statistically significant decrease in both the number 
and adherence of psychiatric/pain management medications as well as antihypertensive 
medications as a result of BMT. These decreases reveal that BMT may play a role in 
positively influencing psychiatric diagnoses as well as chronic pain and cardiovascular 
conditions. These decreases in medication therapy provide the opportunity to pursue 
further investigation into the impact of BMT through assessment scores in order to 
directly track patient symptoms. Though these results are all statistically significant, the 
clinical significance is inconclusive as the large sample sizes may have been the 
underlying driver for statistical significance of most primary endpoints. Further 
investigation is required to verify the clinical significance. This study effectively shows 
that across all of the observed medication classes, medication therapy decreases post 
BMT. This decrease may be attributed to unexplored immune system links to psychiatric 
conditions and/or the effectiveness of BMT increasing overall wellbeing. The interplay 
between BMT and psychiatric diagnoses is not well understood at this time. Mouse 
models and GWAS studies have shown a potential link. This study is the first step in 
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exploring this association in a human population.  There is a need to further investigate 
the long-term effects in this patient population with regard to change in psychiatric 
conditions after BMT. Treatment of major psychiatric conditions could be revolutionized 
by BMT if this connection is verified.  
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Appendices 
Appendix A: ICD 9 and 10 Diagnostic Codes for Psychiatric Conditions and BMT 
 
Disease State ICD-9 CM ICD-10 CM 
Bone Marrow Transplant V42.81 Z94.81 
Encounter for general psychiatric 
examination, requested by authority 
V70.1 Z04.6 
Schizophrenia 295.x F90.x 
Suicide Attempt E950.x T14.91 
Psycho-active Substance Abuse 305.x F19.x 
Opioid-Related Disorders 304.x F11.x 
Bipolar, Manic Depressive and Major 
Depressive Disorders: recurrent 
events 
296.x F33.x 
Bipolar, Manic Depressive and Major 
Depressive Disorders: single events 
311.x F32.x 
Post-traumatic Stress Disorder 309.81 F43.12 
Obsessive-Compulsive Disorder 301.4 R46.81 
Generalized Anxiety Disorder 300.02 F41.1 
Panic Disorder 300.01 F41.0 
Alcohol-Related Disorders 291.x F10.x 
Movement Disorder: stuttering, 
Tourette’s, psychogenic pain 
307.x F95.x 
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Appendix B: Medication Classes and GPI Codes Indicated for Psychiatric Conditions and 
Control Medications (antihypertensives) 
 
ADHD Medications 
Root Classification Secondary Classification Medispan Codes 
Adhd/anti-narcolepsy/anti-
obesity 
Appetite Suppressants 55175x 
Decongestants/Appetite 
Suppressants 
99933x, 41100x, 
11926x, 537x 
Stimulants 99806x, 65162x, 
54092x, 719x, 591x 
Sympathomimetic amines 63187x, 57664x, 
55289x, 54569x, 
677x, 527x 
Wakefulness promoting agents 63459x 
 
 
 
Antianxiety Agents 
Root Classification Secondary Classification Medispan Codes 
Antianxiety Agents  57866x, 57480x, 55175x, 
54124x, 53506x 
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Anticonvulsant Agents 
Root Classification Secondary Classification Medispan Codes 
Neuromuscular Agents, 
Anticonvulsants, Mood 
Stabilizers 
Anticonvulsants, mood 
stabilizers 
51672x, 43353x 
Anticonvulsants/Restless Legs 
Syndrome 
68387x, 66105x, 65162x, 
55048x, 55045x, 33261x, 
21695x, 16590x 
Antiepileptic 76282x, 51079x, 13668x 
Barbiturate anticonvulsants, 
mood stabilizers 
65162x 
Sulfamate-substituted 
monosaccharide 
anticonvulsants 
43063x 
 
 
 
Antidepressants 
Root Classification Secondary Classification Medispan Codes 
Antidepressants Seasonal affective 63739x, 58016x, 54569x 
SNRIs 68382x. 68788x, 
62584x, 63874x, 
61392x, 18837x, 
33261x, 53002x, 
51672x, 33261x. 
21695x, 21695x 
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Antidepressants 
Root Classification Secondary Classification Medispan Codes 
SSRIs 71335x, 63629x, 
62584x, 60429x, 
16590x, 58016x, 
55700x, 54868x, 
47463x, 35356x, 23155x 
Tricyclic antidepressants 406x, 536x, 603x, 
61392x, 54274x 
 
 
Antipsychotics 
Root Classification Secondary Classification Medispan Codes 
Antipsychotics/Antimanic 
Agent 
Antimanic 143x 
Atypical Antipsychotics 99746x, 76282x, 
68001x, 67544x, 
66105x, 60505x, 
49999x, 49848x 
Phenothiazines 51079x, 904x, 725x, 
719x, 536x, 378x 
Typical Antipsychotics 99919x 
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Benzodiazepines 
Root Classification Secondary Classification Medispan Codes 
Benzodiazepines  58016x, 50752x, 904x, 
839x, 603x, 403x, 54x, 
24x 
 
Hypnotics/Sedatives 
Root Classification Secondary Classification Medispan 
Codes 
Hypnotics/Sedatives/Sleep 
Disorders 
Imidazopyridines 67544x, 55887x, 
43063x,  
Other 49999x, 41163x, 
701x, 677x, 
363x, 157x 
 
 
Migraine Medications 
   
Migraine Products Ergot alkaloids 52054x 
Sympathomimetic drug 62584x 
Triptan/Serotonin Receptor 
agonists 
63801x, 62208x, 
540279x, 6026x,4923x,  
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Opioids 
Root Classification Secondary Classification Medispan Codes 
Analgesics  Opioids 99850x, 67457x, 66336x, 
65243x, 63629x, 42358x, 
57866x, 55887x, 55700x, 
55175x, 54868x, 54274x, 
65162x, 52959x, 43386x, 
33358x, 16590x, 10544x 
 
 
Antihypertensives (Control) 
Root Classification Secondary Classification Medispan Codes 
Antihypertensives ACE inhibitors 74x, 603x, 904x, 13811x, 
21695x, 31722x, 52427x, 
50090x, 51285x,  55045x, 
58118x,60760x, 62584x, 
66336x, 67544x, 68788x, 
71335x 
alpha-Agonist 38779x 
ARB inhibitors 42291x, 42658x, 54569x, 
62332x 
CCBs 70934x, 55289x, 54868x, 
54124x, 51138x, 43547xl 
43353x, 16590x 
Combination (ARB and Thiazide 
Diuretics) 
228x, 781x, 52343x, 55700x 
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Antihypertensives (Control) 
Root Classification Secondary Classification Medispan Codes 
Combination (Beta Blocker and 
Thiazide Diuretics) 
378x, 52555x 
Vasodilators 349x, 64380x 
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